Physician profile
Wei Song
NPI 1104826825
$22,372.99
in general payments reported to CMS, 2019-2025
51 companies · $5,629 in 2025
The $5,629 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,391 · 2020: $3,440 · 2021: $3,490 · 2022: $711 · 2023: $2,339 · 2024: $1,373 · 2025: $5,629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,378 · Food and Beverage: $3,463 · Honoraria: $1,400 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,377.50 |
| Food and Beverage | $3,463.20 |
| Honoraria | $1,400.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,299.99 | 2019-2025 | Imfinzi, Enhertu, Tagrisso |
| Lilly USA, LLC | $3,354.05 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Seagen INC. | $2,678.65 | 2019-2023 | Adcetris, Padcev |
| Catalyst Pharmaceuticals, INC. | $1,615.19 | 2023 | Firdapse |
| Kite Pharma, INC. | $1,448.05 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,198.97 | 2019-2025 | Ninlaro, Alunbrig |
| Novartis Pharmaceuticals Corporation | $1,115.09 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,016.46 | 2020-2025 | |
| Beigene, LTD. | $450.00 | 2020 | |
| Merck Sharp & Dohme LLC | $447.38 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Genentech USA, INC. | $436.72 | 2019-2025 | Phesgo, Perjeta, Polivy |
| E.R. Squibb & Sons, L.L.C. | $326.79 | 2019-2025 | Opdualag, Opdivo |
| Pfizer INC. | $313.07 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $296.81 | 2019-2025 | Ultomiris |
| Genzyme Corporation | $287.24 | 2019-2025 |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $274.84 | 2019-2025 | Darzalex, Erleada, Talvey |
| Daiichi Sankyo INC. | $231.76 | 2020-2025 | Enhertu |
| Incyte Corporation | $229.39 | 2019-2025 | Monjuvi, Zynyz, Jakafi |
| Celgene Corporation | $217.43 | 2019-2025 | Reblozyl |
| Novocure Gmbh | $200.00 | 2022 | |
| Sobi, INC | $177.08 | 2022-2025 | |
| Taiho Oncology, INC. | $172.60 | 2019-2025 | |
| Servier Pharmaceuticals LLC | $159.26 | 2021 | |
| Astellas Pharma US INC | $149.51 | 2019-2025 | Padcev |
| Pharmacyclics LLC, An Abbvie Company | $115.23 | 2020-2021 | |
| Exelixis INC. | $101.27 | 2019-2025 | Cabometyx |
| Foundation Medicine, INC. | $96.42 | 2019-2023 | |
| Gilead Sciences, INC. | $93.28 | 2019-2025 | Trodelvy |
| Amgen INC. | $89.21 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Abbvie INC. | $86.00 | 2019-2024 | |
| Stemline Therapeutics INC. | $72.40 | 2024-2025 | Orserdu |
| Rigel Pharmaceuticals, INC. | $68.17 | 2019-2020 | |
| Eisai INC. | $63.41 | 2019 | |
| Pharmacosmos Therapeutics INC. | $52.22 | 2024-2025 | Monoferric |
| Aveo Pharmaceuticals, INC. | $47.46 | 2022-2023 | Fotivda |
| Puma Biotechnology, INC. | $47.30 | 2019-2025 | |
| Cepheid | $39.00 | 2022 | |
| Mirati Therapeutics, INC. | $37.78 | 2024 | Krazati |
| Amag Pharmaceuticals, INC. | $34.95 | 2019-2020 | |
| Tesaro, INC. | $32.37 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $23.62 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $22.70 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $20.59 | 2024 | Libtayo |
| Astellas Pharma Global Development | $20.25 | 2024 | Xtandi |
| Beone Medicines USA, INC. | $20.13 | 2025 | Brukinsa |
| Cti Biopharma Corp. | $18.29 | 2023 | Vonjo |
| Tempus Ai, INC | $17.88 | 2024 | |
| Emd Serono, INC. | $16.38 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.41 | 2025 | |
| Array Biopharma INC | $15.14 | 2020 | |
| Fortovia Therapeutics, INC. | $9.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Song listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.